The immune system on the TRAIL of Alzheimer’s disease

Table 1 Pathophysiological implications of TRAIL in Alzheimer’s disease

Alzheimer’s disease model	TRAIL-based treatment	Main findings	Reference
SH-SY5Y neuronal-like cells	rTRAIL TRAIL-neutralizing monoclonal antibody	TRAIL mediates Aβ-neurotoxicity in vitro	[13]
Human AD brain	/	TRAIL is specifically expressed in Alzheimer’s disease brain	[130]
SH-SY5Y neuronal-like cells Primary mouse cortical neurons	anti-TRAIL-R/DR5 antibody	Blockade of TRAIL-death receptor DR5 signaling prevents Aβ-neurotoxicity in vitro	[133]
3xTgAD	TRAIL-neutralizing monoclonal antibody	Neutralization of TRAIL is associated with functional recovery, decreased Aβ burden and rebalance of both central and peripheral immune response in vivo.	[17]
3xTgAD	TRAIL-neutralizing monoclonal antibody	Neutralization of TRAIL restrain peripheral and CNS inflammatory/immune response along with decreased microglial TNFα production, reduced accumulation of both Aβ and p-Tau protein in the hippocampus of 3xTg-AD mice.	[18]

Summary of the most interesting evidences of the involvement of TRAIL in the pathophysiological events related to neuroinflammatory conditions such as Alzheimer’s disease, in view of a potential future clinical development of TRAIL-based therapeutic strategies

ISSN: 1742-2094